You are here : Home > Research Entities > Service Hospitalier Frédéric Joliot

Service Hospitalier Frédéric Joliot




Published on 23 March 2015

The Service Hospitalier Frédéric Joliot (SHFJ), directed by Vincent Lebon, is a molecular and functional imaging center located on the Orsay hospital site. It ensures a public service mission and a research and development mission in biomedical imaging and in diagnostic and therapeutic innovation. The aim of this research is to create new imaging tools to improve diagnosis and evaluation of innovative therapeutics in three thematic areas :

  • oncological diseases,
  • neurodegenerative, neuro-inflammatory, psychiatric and addiction disorders,
  • cardiovascular, metabolic and systemic inflammatory diseases.

SHFJ is divided in 3 entities : the Nuclear Medicine Service, that ensures the public service mission of the SHFJ, the In Vivo Molecular Imaging Laboratory (IMIV), a Mixed Research Unit (UMR 1023) belonging to CEA, Inserm and Paris-Sud University and the Laboratory for Methodological Developments in PET (LDM/TEP), based in Caen. The SHFJ has also a branch of the pharmacy for internal use of the Orsay Hospital for 2 activities, namely the preparation of radiopharmaceuticals and the preparations for biomedical research including the experimental medicines one (Arrêté n° 08-065-91 du 23/05/2008).

(click on image to enlarge)


Moreover, the SHFJ is associated with three other Research Entities (Associated Units) : the Medical Magnetic Resonance Imaging and Multi-Modalities Unit (IR4M), the research team in clinical imaging of neurodegenerative diseases, and the Research Team "Child Epilepsy and Cerebral Plasticity".

To carry out their Research, SHFJ researchers have access to platforms, part of the National Infrastructures in Biology and Health France Life Imaging (FLI) et NeurATRIS financed by the Programme of Investments for the Future (PIA) :

  • PRIME (certified IBiSA) : Experimental Molecular Imaging Research Platform, a platform dedicated to preclinical and clinical molecular imaging,
  • IRM 1,5T : a clinical IRM.


Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats
Amor D., Goutal S., Marie S., Caille F., Bauer M., Langer O., Auvity S. and Tournier N.
P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of (11)C-metoclopramide across the blood-brain barrier: a PET study on non-human primates
Auvity S., Caille F., Marie S., Wimberley C., Bauer M., Langer O., Buvat I., Goutal S. and Tournier N.
Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using (11) C-Metoclopramide PET Imaging
Auvity S. and Tournier N.
Effect of Rifampicin on the Distribution of [(11)C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice
Bauer M., Traxl A., Matsuda A., Karch R., Philippe C., Nics L., Klebermass E. M., Wulkersdorfer B., Weber M., Poschner S., Tournier N., Jager W., Wadsak W., Hacker M., Wanek T., Zeitlinger M. and Langer O.
Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia
Bergeron D., Gorno-Tempini M. L., Rabinovici G. D., Santos-Santos M. A., Seeley W., Miller B. L., Pijnenburg Y., Keulen M. A., Groot C., van Berckel B. N. M., van der Flier W. M., Scheltens P., Rohrer J. D., Warren J. D., Schott J. M., Fox N. C., Sanchez-Valle R., Grau-Rivera O., Gelpi E., Seelaar H., Papma J. M., van Swieten J. C., Hodges J. R., Leyton C. E., Piguet O., Rogalsky E. J., Mesulam M. M., Koric L., Nora K., Pariente J., Dickerson B., Mackenzie I. R., Hsiung G. R., Belliard S., Irwin D. J., Wolk D. A., Grossman M., Jones M., Harris J., Mann D., Snowden J. S., Chrem-Mendez P., Calandri I. L., Amengual A. A., Miguet-Alfonsi C., Magnin E., Magnani G., Santangelo R., Deramecourt V., Pasquier F., Mattsson N., Nilsson C., Hansson O., Keith J., Masellis M., Black S. E., Matias-Guiu J. A., Cabrera-Martin M. N., Paquet C., Dumuirger J., Teichmann M., Sarazin M., Bottlaender M., Dubois B., Rowe C. C., Villemagne V. L., Vandenberghe R., Granadillo E., Teng E., Mendez M., Meyer P. T., Frings L., Lleo A., Blesa R., Fortea J., Seo S. W., Diehl-Schmid J., Grimmer T., Frederiksen K. S., Sanchez-Juan P., Chetelat G., Jansen W., Bouchard R. W., Robert L., Jr., Visser P. J. and Ossenkoppele R.
Rapid Contour-based Segmentation for (18)F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation
Besson F. L., Henry T., Meyer C., Chevance V., Roblot V., Blanchet E., Arnould V., Grimon G., Chekroun M., Mabille L., Parent F., Seferian A., Bulifon S., Montani D., Humbert M., Chaumet-Riffaud P., Lebon V. and Durand E.
Influence of age on radiomic features in (18)F-FDG PET in normal breast tissue and in breast cancer tumors
Boughdad S., Nioche C., Orlhac F., Jehl L., Champion L. and Buvat I.
Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide
Caille F., Goutal S., Marie S., Auvity S., Cisternino S., Kuhnast B., Pottier G. and Tournier N.
Can we trust the calculation of texture indices of CT images? A phantom study
Caramella C., Allorant A., Orlhac F., Bidault F., Asselain B., Ammari S., Jaranowski P., Moussier A., Balleyguier C., Lassau N. and Pitre-Champagnat S.
Unmixing dynamic PET images with variable specific binding kinetics
Cavalcanti Y. C., Oberlin T., Dobigeon N., Stute S., Ribeiro M. and Tauber C.
(18)F-Fludarabine-PET for lymphoma imaging: first-in-man study in DLBCL and CLL patients
Chantepie S., Hovhannisyan N., Guillouet S., Pelage J. P., Ibazizene M., Bodet-Milin C., Carlier T., Gac A. C., Reboursiere E., Vilque J. P., Kraeber-Bodere F., Manrique A., Damaj G., Leporrier M. and Barre L.
Planning and management of SEEG
Chassoux F., Navarro V., Catenoix H., Valton L. and Vignal J. P.
Electrocorticographic telemetric recording in unrestrained mouse pups
Chemaly N., Nehlig A., Chiron C. and Nabbout R.
Cross-sectional variations of white and grey matter in older hypertensive patients with subjective memory complaints
Chetouani A., Chawki M. B., Hossu G., Kearney-Schwartz A., Chauveau-Beuret F., Bracard S., Roch V., Lebon V., Marie P. Y., Benetos A., Joly L. and Verger A.
Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Cottereau A. S., Buvat I., Kanoun S., Versari A., Casasnovas O., Chauvie S., Clerc J., Gallamini A. and Meignan M.
Magnetic resonance elastography of the lumbar back muscles: A preliminary study
Creze M., Soubeyrand M., Yue J. L., Gagey O., Maitre X. and Bellin M. F.
Issues in quantification of registered respiratory gated PET/CT in the lung
Cuplov V., Holman B. F., McClelland J., Modat M., Hutton B. F. and Thielemans K.
Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis
Darnaud M., Dos Santos, A., Gonzalez P., Augui S., Lacoste C., Desterke C., De Hertogh, G., Valentino E., Braun E., Zheng JZ., Boisgard R., Neut C., Dubuquoy L., Chiappini F., Samuel D., Lepage P., Guerrieri F., Dore J., Brechot C., Moniaux N. and Faivre J.
Late-stage isotopic carbon labeling of pharmaceutically relevant cyclic ureas directly from CO2
Del Vecchio A., Caille F., Chevalier A., Loreau O., Horkka K., Halldin C., Schou M., Camus N., Kessler P., Kuhnast B., Taran F. and Audisio D.
(18)F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI
Desarnaud S., Mellerio C., Semah F., Laurent A., Landre E., Devaux B., Chiron C., Lebon V. and Chassoux F.
Correction to: (18)F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI
Desarnaud S., Mellerio C., Semah F., Laurent A., Landre E., Devaux B., Chiron C., Lebon V. and Chassoux F.
Neutrophil hyperactivation correlates with Alzheimer's disease progression
Dong Y., Lagarde J., Xicota L., Corne H., Chantran Y., Chaigneau T., Crestani B., Bottlaender M., Potier M. C., Aucouturier P., Dorothee G., Sarazin M. and Elbim C.
Optical and thermal simulations for the design of optodes for minimally invasive optogenetics stimulation or photomodulation of deep and large cortical areas in non-human primate brain
Dubois A., Chiang C. C., Smekens F., Jan S., Cuplov V., Palfi S., Chuang K. S., Senova S. and Pain F.
Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study
Dubol M., Trichard C., Leroy C., Sandu A. L., Rahim M., Granger B., Tzavara E. T., Karila L., Martinot J. L. and Artiges E.
How to Improve Quality in IRBM Publications?
Frouin F. and Melodelima D.
Validation of an automatic reference region extraction for the quantification of [(18)F]DPA-714 in dynamic brain PET studies
Garcia-Lorenzo D., Lavisse S., Leroy C., Wimberley C., Bodini B., Remy P., Veronese M., Turkheimer F., Stankoff B. and Bottlaender M.
Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease
Gargouri F., Gallea C., Mongin M., Pyatigorskaya N., Valabregue R., Ewenczyk C., Sarazin M., Yahia-Cherif L., Vidailhet M. and Lehericy S.
Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib
Goutal S., Gerstenmayer M., Auvity S., Caille F., Meriaux S., Buvat I., Larrat B. and Tournier N.
Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates
Goutal S., Langer O., Auvity S., Andrieux K., Coulon C., Caille F., Gervais P., Cisternino S., Decleves X. and Tournier N.
Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma
Goya-Outi J., Orlhac F., Calmon R., Alentorn A., Nioche C., Philippe C., Puget S., Boddaert N., Buvat I., Grill J., Frouin V. and Frouin F.
1 - 30Next